# CardioKinetix

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cardiokinetix

- Industry: Medical Devices & Equipment
- Headquarters: Menlo Park, US
- Website: www.cardiokinetix.com
- Total disclosed funding: $111M
- Latest round: Series F (Dec 5, 2014)
- Investors on record: 9

## About

CardioKinetix Inc. is a biomedical company specializing in advanced medical devices aimed at treating heart failure through innovative, minimally invasive interventions that enhance cardiac function and improve patient outcomes.Founded in 2002 and headquartered in Menlo Park, California, CardioKinetix develops unique implantable devices for heart failure treatment, focusing on improving hemodynamics. The company raised USD 30.71 mn in Series F funding in December 2014 from investors including Edwards Lifesciences Corporation. It has completed 8 deals since inception.CardioKinetix specializes in innovative medical devices aimed at treating heart failure, focusing on enhancing cardiac function through minimally invasive interventions. Their flagship product is an implantable device that provides immediate and long-term relief for heart failure patients. The company targets diverse healthcare clients, including hospitals and specialists, primarily operating in North America and select regions in Europe.CardioKinetix generates revenue through direct sales of its medical devices to healthcare providers and institutions, with transactions structured as one-time purchases for surgical procedures. The company has established partnerships to integrate its technology into clinical practices, with pricing that reflects the advanced nature of its products and their benefits for patient care.CardioKinetix aims to expand its product line with upcoming devices designed to address heart failure more effectively. The company plans to enter new markets, particularly in Europe and Asia, by 2025. The funding raised in December 2014 will support these product developments and market expansions.

## Funding rounds

- Series F, Dec 5, 2014, $31M — US Venture Partners, SV Health Investors, Panorama Capital, Edwards Lifesciences Corporation, New Leaf Venture Partners, Tekla Capital Management, Lexington Partners
- Series E, Aug 15, 2014, $3M — US Venture Partners
- Series E, Feb 28, 2013, $17M — US Venture Partners, SV Health Investors, Panorama Capital, New Leaf Venture Partners, Tekla Capital Management
- Series E, Sep 21, 2011, $25M — US Venture Partners, SV Health Investors, Panorama Capital, New Leaf Venture Partners, Tekla Capital Management, JP Morgan Asset Management
- Series D, Dec 10, 2010, $9.3M — US Venture Partners, Panorama Capital
- Series C, May 2, 2008, $13M — US Venture Partners, Cutlass Capital, Tekla Capital Management, JP Morgan Asset Management
- Series B, Apr 18, 2006, $7.5M — US Venture Partners
- Series A, Apr 5, 2004, $5.6M — US Venture Partners

## Investors

- US Venture Partners (https://capitalatlas.ai/funds/us-venture-partners) — Series A, Series B, Series C, Series D, Series E, Series F
- Cutlass Capital (https://capitalatlas.ai/funds/cutlass-capital) — Series C
- Tekla Capital Management (https://capitalatlas.ai/funds/tekla-capital-management) — Series C, Series E, Series F
- JP Morgan Asset Management (https://capitalatlas.ai/funds/jp-morgan-asset-management) — Series C, Series E
- Panorama Capital — Series D, Series E, Series F
- SV Health Investors (https://capitalatlas.ai/funds/sv-health-investors) — Series E, Series F
- New Leaf Venture Partners (https://capitalatlas.ai/funds/new-leaf-venture-partners) — Series E, Series F
- Edwards Lifesciences Corporation — Series F
- Lexington Partners (https://capitalatlas.ai/funds/lexington-partners) — Series F